Categories
Change Password!
Reset Password!
With rapid onset of action and considerable tolerability, Anakinra is a potent therapeutic treatment for acute attacks of gout or CPP crystal arthritis.
Anakinra improves or resolves 75% of episodes of acute gout and calcium pyrophosphate crystal arthritis within four days of the first dose, evident from a retrospective observational study issued in the Journal of Rheumatology.
The
analysis comprised patients who treated with Anakinra from 2014-2017.
Charts were analysed for laboratory data, comorbidities,
demographics, pain scores, concurrent infections, joint involvement,
surgical interventions, prior treatment, and dosing and response to
Anakinra. Recorded pain scores on a numeric scale and review of
provider documentation have defined the response to Anakinra
treatment.
A
total of 115 episodes of arthritis was identified. Comorbidities
occurred with such type of arthritis were the history of organ
transplantation and renal disease. Thirty-four episodes found to have
a concurrent infection, whereas 29 episodes found in the
perioperative setting. Sixty-six episodes exhibited a partial or
complete response in just one day, whereas eighty-four episodes
showed within four days after the treatment initiation. All patients
exhibited well-tolerability toward Anakinra. This most extensive
observational study also promotes the application of this biologic
agent among people with infections, immunosuppressed transplant
recipients, and perioperative individuals.
The Journal of Rheumatology
Use of Anakinra in Hospitalised Patients with Crystal-associated Arthritis.
Jean W. Liew & Gregory C. Gardner
Comments (0)